CompletedNot Applicable

Graded TTCE for Post-Embolization PAVM Monitoring

United States32 participantsStarted 2016-10

Plain-language summary

Current HHT guidelines recommend CT scan to detect new or recurrent PAVMs after embolotherapy. Recent studies using transthoracic contrast echocardiography (TTCE) shunt grade for PAVM screening suggest that graded TTCE can accurately predict the size of PAVMs on chest CT and their amenability to embolization. This study's purpose is to evaluate whether TTCE shunt grade can also accurately predict PAVM size and amenability to treatment in patients who are post-embolization.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age range 18-89 years old * Diagnosis of Hereditary Hemorrhagic Telangiectasia by the Curacao criteria * Prior diagnosis of one or more PAVMs treated by embolotherapy * Chest CT performed within the Penn system for surveillance of PAVMs after \\ embolotherapy Exclusion Criteria: * Known PAVM recurrence on most recent chest CT with feeding artery size amenable to repeat embolotherapy * Known history of intracardiac shunt * Discovery of intracardiac shunt during transthoracic contrast echocardiography

What they're measuring

Differences between TTCE shunt grade and the number of PAVMs present on most recent chest CT scan.

Timeframe: At the time of the echocardiogram (TTCE)

Differences between TTCE shunt grade and the size of PAVMs present on most recent

Timeframe: At the time of the echocardiogram (TTCE)

Trial details

NCT IDNCT02936349

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-11

View on ClinicalTrials.gov More Hereditary Hemorrhagic Telangiectasia (HHT) trials